Regulatory Viridian wins FDA approval for Lumvoa for thyroid eye disease PharmaTimesCompany secures first commercial product with data for active and chronic TEDOphthalmologyRead full story pharminent June 29, 2026 (Last updated: June 30, 2026) PharmaTimes Company secures first commercial product with data for active and chronic TED Ophthalmology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Ipsen charts $1.75bn course for Kartos acquisitionNext: Biogen trims Apellis pipeline and R&D team after $5.6bn takeover Related Stories Regulatory Celcuity gains FDA approval for closely watched breast cancer drug pharminent July 15, 2026 Regulatory Celcuity gets FDA nod for first-in-class breast cancer drug pharminent July 15, 2026 Regulatory FDA clears at-home start dose for Alzheimer’s drug Leqembi pharminent July 14, 2026
